H.C. Wainwright Downgrades ChemoCentryx (CCXI) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CCXI Hot Sheet
Price: $9.94 -3.02%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 16
Join SI Premium – FREE
H.C. Wainwright analyst Edward White downgraded ChemoCentryx (NASDAQ: CCXI) from Buy to Neutral with a price target of $52.00 (from $101.00).
For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.
Shares of ChemoCentryx closed at $50.43 yesterday.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Ligand Pharma (LGND) PT Raised to $350 at Stifel
- Stifel Downgrades Alnylam Pharmaceuticals (ALNY) to Hold
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
